Stockscreener 앱 받기
15.25
0.28%
0.043
시간 외 거래:
15.90
0.65
+4.26%
Polyrizon Ltd 주식(PLRZ)의 최신 뉴스
Polyrizon Clears Key Safety Milestone for NASARIX Allergy Nasal Spray - TipRanks
Polyrizon (PLRZ) clears NASARIX biocompatibility milestone toward first human trial - Stock Titan
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) - Yahoo Finance
Polyrizon completes biocompatibility tests for allergy nasal spray - Investing.com
Polyrizon stock rises on biocompatibility test results By Investing.com - Investing.com Nigeria
Polyrizon completes biocompatibility tests for allergy nasal spray By Investing.com - Investing.com India
Polyrizon Announces Successful Biocompatibility Results for NASARIX Allergy Blocker Nasal Spray - Quiver Quantitative
Polyrizon’s allergy nasal spray clears safety tests, advancing human trial plans - Stock Titan
Polyrizon Advances on Test Results - Baystreet.ca
Polyrizon Wins Central IRB Nod for First NASARIX Allergy Blocker Trial - TipRanks
[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC FilingForm 6-K - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Polyrizon receives IRB approval for nasal spray clinical trial - Investing.com
Polyrizon receives IRB approval for nasal spray clinical trial By Investing.com - Investing.com Canada
Polyrizon Receives Central IRB Approval for First Human Clinical Trial of NASARIX Allergy Blocker - Quiver Quantitative
Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial - The Manila Times
Polyrizon clears review to start first NASARIX human allergy trial - Stock Titan
Enterprise value to revenue forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Enterprise value to EBITDA forward of Polyrizon Ltd. – NASDAQ:PLRZ - TradingView
Polyrizon Ltd (PLRZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Polyrizon receives US patent publication notice for nasal drug delivery platform - MSN
Polyrizon Ltd. Ordinary Shares (NASDAQ: PLRZ) Stock Price, News & Analysis - Kalkine
Polyrizon (PLRZ) Stock Price, News & Analysis - MarketBeat
Polyrizon Ltd (PLRZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Polyrizon Ltd (PLRZ) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Polyrizon Ltd (PLRZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Polyrizon Announces U.S. Publication of Mucoadhesive Nasal Drug Delivery Patent - TipRanks
Polyrizon (Nasdaq: PLRZ) details U.S. patent publication for Trap & Target nasal platform - Stock Titan
Polyrizon announces U.S. patent application publication - Investing.com
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform - The Manila Times
Polyrizon patent published for nasal drug-delivery technology - Stock Titan
Polyrizon announces U.S. patent application publication By Investing.com - Investing.com UK
Polyrizon Ltd (PLRZ) Institutional Confidence - TradingKey
Polyrizon Ltd (PLRZ) Valuation: PE, PB & Fair Value Analysis - TradingKey
Polyrizon Ltd (PLRZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Polyrizon Ltd (PLRZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Polyrizon Ltd (PLRZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Polyrizon Launches Key Human Study to Advance NASARIX Allergy Blocker Toward FDA Pathway - TipRanks
Polyrizon (PLRZ) launches NASARIX™ human study to assess nasal residence and aid FDA path - Stock Titan
Polyrizon stock surges on human study for allergy blocker By Investing.com - Investing.com South Africa
Polyrizon stock surges on human study for allergy blocker - Investing.com
Polyrizon Ltd. Enters Agreement With European University Medical Center And Clinical Research Organization For Human Study Of NASARIX? - marketscreener.com
Polyrizon initiates nasal residence time study for allergy blocker By Investing.com - Investing.com Australia
Polyrizon initiates nasal residence time study for allergy blocker - Investing.com
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway - The Manila Times
How long can a nasal allergy blocker stay put? New human study aims to find out - Stock Titan
Polyrizon Wins European Patent Publication for Mucoadhesive Nasal Drug Delivery Platform - TipRanks
Polyrizon (Nasdaq: PLRZ) moves ahead on European nasal drug patent - Stock Titan
Polyrizon Marches on European Patent - Baystreet.ca
Polyrizon receives European patent application publication - Investing.com
Polyrizon receives European patent application publication By Investing.com - Investing.com South Africa
Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology - The Manila Times
Polyrizon Ltd. Announces Publication of European Patent Application for Innovative Nasal Drug Delivery Technology - Quiver Quantitative
Polyrizon Sets July 13, 2026 AGM to Vote on Board, Pay and Auditor Mandates - The Globe and Mail
Polyrizon schedules annual shareholder meeting for July 13 By Investing.com - Investing.com Canada
Polyrizon Secures Three Key U.S. Sites for NASARIX Allergy Trial - TipRanks
1.17%
2.48%
자본화:
|
볼륨(24시간):